+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

A

Actively Recruiting

Researchers are evaluating the safety and effectiveness of tenapanor in adults with Chronic Idiopathic Constipation CIC. This study is a 26-week, multi-center, randomized, double-blind, placebo-controlled trial followed by a 4-week treatment-free safety follow-up period. It aims to compare three different doses of tenapanor with a placebo taken twice daily to assess their impact on constipation symptoms. The study includes a 2-week screening period to confirm eligibility, followed by a 26-week randomized treatment period where patients receive either 5 mg, 25 mg, or 50 mg of tenapanor twice daily, or a matching placebo. Patients record their constipation symptoms daily in an electronic diary. After the treatment period, there is a 4-week safety follow-up without treatment to monitor any adverse effects. Participants will have regular visits every 2 to 6 weeks for safety checks including medical assessments, vital signs, ECG, and lab tests. Their symptom diaries will be reviewed throughout the study. The main outcome measured is the durable complete spontaneous bowel movements response at 12 weeks. Secondary outcomes include changes in bowel movement frequency, stool consistency, and straining. The total study duration is approximately 32 weeks including all phases.

Age: 18Years - 80YearsAll GendersPhase 3
109 locations
C

Actively Recruiting

Researchers are evaluating the effectiveness of dotinurad compared with allopurinol in lowering serum uric acid levels in adults with gout-related hyperuricemia. This Phase 3 randomized study focuses on measuring the proportion of participants achieving target serum uric acid levels at Week 24. It aims to provide insights into treatment options for people living with gout. Participants will be randomly assigned to one of three groups one group will continue allopurinol at their current stable dose once daily through Week 64, while the other two groups will receive dotinurad with dose escalation over time. Dotinurad dosing starts at 1 mg daily for the first 4 weeks, increasing to 2 mg daily through Week 64 for one group, and for the other group, it increases from 1 mg daily for 4 weeks to 2 mg daily for 8 weeks, then 4 mg daily through Week 64. Throughout the study, participants will undergo regular assessments including serum uric acid level measurements and gout flare monitoring from baseline through Week 68. Safety will also be tracked by recording adverse events. The main outcome is the percentage of participants with serum uric acid below 6.0 mgdL at Week 24. The total study duration per participant extends up to approximately 68 weeks, with ongoing evaluations to assess gout flare frequency and other relevant outcomes.

Age: 18Years - 75YearsAll GendersPhase 3
119 locations
P

Actively Recruiting

Researchers are studying the effectiveness of dotinurad compared to allopurinol in lowering serum uric acid levels in adults with tophaceous gout. This Phase 3, randomized, double-blind trial focuses on adults aged 18 to 75 years diagnosed with gout for at least one year who have measurable tophi. The study aims to evaluate how well dotinurad lowers uric acid at Week 24 compared to allopurinol. Participants are divided into two groups. One group stops their current allopurinol and takes study-provided allopurinol once daily up to Week 76. The other group stops their prior allopurinol and starts dotinurad, beginning with 1 mg daily for the first 4 weeks, increasing to 2 mg daily for 8 weeks, then 4 mg daily through Week 76. Both treatments involve oral capsules taken once a day. This approach allows comparison of the two drugs effects over an extended treatment period. During the study, participants will have regular assessments to monitor serum uric acid levels, tophi response, and gout flare frequency up to Week 80. Safety is tracked by recording any adverse events. Data collected will include changes in uric acid, tophi area, and flare rates. Participants remain in the study for over a year, with frequent visits for evaluations and treatment adherence checks.

Age: 18Years - 75YearsAll GendersPhase 3
96 locations
E

Actively Recruiting

Seasonal influenza affects about one billion people worldwide each year, with 3 to 5 million cases being severe and causing up to 650,000 deaths annually. Vaccine effectiveness varies widely, often below 50%, and can be as low as 5% in people with weakened immune systems. This study aims to evaluate whether MK-1406 CD388 can help prevent influenza in adolescents and adults who are at increased risk of serious illness due to age, health conditions, or immune system weakness. Participants will receive a single dose of MK-1406 or a placebo through three subcutaneous injections during one study visit. The study is a Phase 3, randomized, double-blind, placebo-controlled trial conducted at multiple centers. It compares the safety, tolerability, and effectiveness of MK-1406 against placebo for preventing influenza in higher-risk individuals. During the study, participants will be monitored for up to approximately 24 weeks to track the occurrence of influenza-like illness, adverse events, and other health outcomes. Blood samples will be collected at specific times to measure drug levels and immune responses. Safety will be closely followed, including monitoring for injection site reactions and treatment-related antibodies. Participants health will be observed throughout the study period ending around 24 weeks post-dose.

Age: 12Years +All GendersPhase 3
185 locations
R

Actively Recruiting

Researchers are studying the effects and safety of SPN-812 viloxazine extended release in children aged 4 to 5 years who have Attention-DeficitHyperactivity Disorder ADHD. This study is a Phase 4, randomized, double-blind, placebo-controlled trial designed to compare SPN-812 with a placebo in preschool-age children diagnosed with ADHD. The goal is to evaluate how well the medication works and how tolerable it is in this young population. Participants will be randomly assigned to receive either 100mg SPN-812 or a placebo once daily for a 6-week treatment period. Before starting treatment, children will be screened for up to 4 weeks to determine eligibility. The total study duration for each participant is up to 10 weeks, including screening and treatment. This design allows researchers to compare the effects of SPN-812 against placebo over a set timeframe. During the study, participants will be evaluated using the ADHD Rating Scale, 4th Edition, Preschool Version ADHD-RS-IV-P to measure changes in ADHD symptoms. Other assessments include the Clinical Global Impression of Severity and Change scores. Parents or guardians will provide consent, and children will be regularly monitored for safety and treatment response. Researchers will collect data at baseline and at the end of the 6-week treatment period to assess the medications impact and any side effects.

Age: 48Months - 69MonthsAll GendersPhase 4
54 locations
E

Actively Recruiting

Researchers are evaluating AXS-14 esreboxetine for managing fibromyalgia in a Phase 3, double-blind, placebo-controlled, randomized withdrawal study. The study aims to assess the efficacy and safety of AXS-14 for people diagnosed with fibromyalgia based on the 2016 ACR diagnostic criteria. The trial includes a multi-center design with two main periods. First, participants receive open-label AXS-14 tablets once daily for up to 12 weeks. Those who respond to treatment are then randomized to either continue AXS-14 or switch to placebo for an additional 12 weeks or until loss of therapeutic response occurs. Participants will be involved for up to 24 weeks in total. During this time, they will take study tablets daily and undergo assessments to monitor their response and safety. The primary outcome measured is the time from randomization to loss of therapeutic response over 12 weeks. Safety and efficacy are closely monitored throughout the study.

Age: 18Years +All GendersPhase 3
53 locations